Redcare Pharmacy’s Prescription Boom Collides with Margin Squeeze as Investors Flee

The online pharmacy is delivering blistering top-line growth, yet its stock keeps sliding. Redcare Pharmacy finished last week at €44.52, down 2.11% on Friday alone and 4.5% lower over the full week. Since the start of the year, shareholders have lost roughly a third of their investment. The sell-off reflects a deepening doubt: can this company make decent money from the prescription drugs that are fuelling its expansion?

First-quarter revenue jumped more than 18% to nearly €850 million, and the adjusted operating result improved meaningfully. The active customer base swelled past 14 million. But the gross margin shrank from 23.3% to 21.0%, squeezed by the very engine of growth. Redcare’s digital CardLink solution is pushing ever more prescription medicines through its platform—high-volume, low-margin business that dilutes overall profitability. The net loss edged down only slightly to €10.5 million.

Analysts see a different story. Their average price target stands at roughly €74, implying a 67% upside from current levels. Six experts rate the stock a buy; none recommend a sale. Deutsche Bank and Berenberg both reaffirmed their positive calls in May, while Kepler Capital stuck with a neutral rating. Yet the market continues to price in a far gloomier scenario. Over the past twelve months the shares have shed about 65% of their value, and the gap to the 200-day moving average has widened to almost 30%.

Management turnover is adding another layer of uncertainty. Chief Commercial Officer Dirk Brüse has announced his departure, and Hendrik Krampe—a former Amazon executive with eight years of experience at the e-commerce giant—steps in as the new Chief Financial Officer. The reshuffle comes at a delicate moment when Redcare is pumping cash into a new logistics hub in Pilsen, Czech Republic, to expand capacity dramatically.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

The payoff from that investment remains distant. Redcare has declared this year an “investment year,” and the spending is eating into earnings. The company slashed its medium-term margin target from 8% to just over 5%. For the current fiscal year, management still expects an adjusted operating margin of at least 2.5% and revenue growth of 13–15%. So far, investors are voting with their feet.

Technically, the outlook looks precarious. The MACD has issued a clear sell signal. The next major support lies at €42.06; if that gives way, the yearly low of €31.00 could quickly come into play. On the upside, resistance around €46 is blocking any swift recovery.

The structural backdrop, however, offers some comfort. Germany’s network of brick-and-mortar pharmacies is shrinking fast, pushing more prescription volume into digital channels. Redcare already commands a 67% share of the online prescription market. A government commission has recommended raising statutory co-payments for prescription drugs, a change that could boost Redcare’s revenue further. The company expects to generate over €670 million from the prescription segment this year alone.

Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.

Redcare’s challenge is to convert that dominance and growth into sustainable profitability. The investment phase is slated to ease markedly from 2027 onward. Until then, the stock is caught between a booming prescription business and a margin squeeze that shows no sign of letting up.

Ad

Redcare Pharmacy Stock: New Analysis - 24 May

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

en | NL0012044747 | REDCARE | boerse | 69409323 |